The relation between intermittent dosing and adherence: Preliminary insights
References (17)
- et al.
Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study
Clin Ther
(2003) - et al.
A systematic review of the associations between dose regimens and medication compliance
Clin Ther.
(2001) - et al.
The impact of reducing dose frequency on health outcomes
Clin Ther
(2003) - et al.
Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women
- et al.
Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: A 1-year randomized trial
Contraception
(2005) - et al.
Preference for and sat isfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: An open-label, multicentre study
J Obstetr Gynaecol Can
(2005) - et al.
Patient preference for once weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, openlabel, crossover study
Clin Ther
(2002) - et al.
Patients with osteoporosis prefer once weekly to once daily dosing with alendronate
Maturitas
(2004)
Cited by (67)
Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics
2021, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Unlike ICS/LABA controllers, which must be used every day, most biologics are dosed once or twice a month. Medication possession ratios and treatment persistence have been found to be higher in medications dosed weekly or monthly versus those dosed daily.18-20 Patients who find it difficult to maintain consistent use of a daily controller medication may want to try a less frequently administered controller.
Post-use ring weight and residual drug content as potential objective measures of user adherence to a contraceptive progesterone vaginal ring
2019, ContraceptionCitation Excerpt :This assumption is particularly prevalent in the HIV microbicide and multipurpose prevention technology fields, which are heavily focused on new vaginal ring technologies [1–6]. Based on adherence data from other clinical indications [7–9], including hormonal contraception for which depot injections, sub-dermal implants, transdermal patches and vaginal rings are available [10,11], the case for sustained/controlled drug delivery is generally well made and widely accepted. However, a major challenge in vaginal ring product development remains the accurate measurement of adherence in late stage clinical trials [3,12,13], as recently highlighted by the results of the dapivirine ring trials demonstrating increased efficacy in women showing high levels of adherence [14,15].
Rapid generation of a novel DPP-4 inhibitor with long-acting properties: SAR study and PK/PD evaluation
2017, European Journal of Medicinal ChemistryMicrobicide vaginal rings: Technological challenges and clinical development
2016, Advanced Drug Delivery ReviewsCitation Excerpt :It has long been assumed that use of sustained or controlled release delivery systems for vaginal administration of microbicides to prevent infection with HIV will lead to increased microbicide product adherence, acceptability and efficacy compared with more conventional, coitally-dependent, vaginal formulations by simplifying use instructions and requiring less user behavior [15,16,56,215]. Indeed, based on adherence data from other clinical indications [204,216,217], including hormonal contraception for which long-acting depot injections, sub-dermal implants, transdermal patches and VRs are available [218,219], the case for sustained/controlled release of HIV microbicides is generally well made and widely accepted. Previous studies have reported high levels of user adherence to VRs for non-microbicide clinical indications.
Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: A randomised, double-blind, phase 3, non-inferiority study
2015, The Lancet Diabetes and EndocrinologyCitation Excerpt :Adherence to treatment for type 2 diabetes is generally better with less frequent dosing.9,11,12,19–21 Patients with chronic illnesses generally prefer intermittent dosing (less than once per day) to once-daily dosing, and a once-weekly oral therapy could improve adherence.8,22 The availability of a once-weekly oral drug for type 2 diabetes might provide an additional treatment option for patients and physicians.
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
2023, Nature Reviews Drug Discovery